Corbus Pharmaceuticals (NASDAQ:CRBP) held its annual meeting of stockholders by remote communication, with shareholders approving all five proposals presented at the meeting, according to remarks and preliminary voting results delivered during the event.
Rachelle Jacques, chair of the board of directors of Corbus Pharmaceuticals Holdings, presided over the meeting. She introduced company representatives in attendance, including Dr. Yuval Cohen, chief executive officer; Sean Moran, chief financial officer; and Meghan Houghton, vice president of finance. Representatives from Lowenstein Sandler LLP, the company’s outside corporate and securities counsel, and EisnerAmper LLP, its independent registered public accounting firm, also attended.
Quorum established for annual meeting
The operator reported that the company’s board selected March 23, 2026, as the record date for the meeting. On that date, Corbus had 17,736,464 shares of common stock outstanding.
A total of 14,134,370 shares of common stock were present in person or by proxy, representing the holders of at least one-third of the voting power of the company’s capital stock issued and outstanding and entitled to vote, as well as at least one-third of the company’s common stock issued and outstanding and entitled to vote. Based on that report, Jacques said a quorum was present and the meeting could proceed.
Shareholders approve all proposals
The five matters presented to shareholders were moved by Cohen, acting as a stockholder, and seconded by an unidentified shareholder. According to the preliminary report from the inspector of elections, each proposal received the required level of support.
- Shareholders elected Yuval Cohen, Rachelle Jacques, John Jenkins, Anne Altmeyer, Yong Ben and Winston Kung as directors for the terms described in the proxy statement.
- Shareholders approved an amendment to the Corbus Pharmaceuticals Holdings, Inc. 2024 Equity Compensation Plan to increase the number of shares authorized for issuance under the plan by 3 million shares to 5 million shares.
- Shareholders ratified the appointment of EisnerAmper LLP as the company’s independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
- Shareholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers as described in the proxy statement.
- Shareholders voted, on a non-binding advisory basis, in favor of holding future advisory votes on executive compensation every year.
The operator said each of the six director nominees was elected by a plurality of the votes of shares present in person or represented by proxy and entitled to vote. The equity plan amendment, auditor ratification and advisory executive compensation vote were each approved by a majority of votes cast. On the advisory vote regarding the frequency of future say-on-pay votes, the majority of votes were cast for a one-year frequency.
No shareholder questions raised during meeting
Jacques said the company would provide time for general questions after the formal portion of the meeting, with only validated stockholders permitted to ask questions through the web portal. She said the company would address questions germane to the meeting but would not provide material non-public information.
When Jacques introduced Cohen to take stockholder questions or comments regarding the proposals or the company generally, she said there were no questions at that time. Cohen then ended the question-and-comment period and said stockholders could write to him care of the company if they had questions or comments they wished to address.
Jacques said the final results of each proposal will be disclosed in a current report on Form 8-K to be filed within four business days. The meeting was then adjourned following a motion by Cohen and a second from an unidentified shareholder.
About Corbus Pharmaceuticals (NASDAQ:CRBP)
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.
Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.
